SCOTTS INTERNATIONAL

Antacids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-08-01 | 115 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License $4750.00
- Team License (1-7 Users) $5250.00
- Site License $6500.00
- Corporate License $8750.00

Report description:

Antacids Market Analysis

The antacids market size is valued at USD 7.06 billion in 2025 and is forecast to reach USD 8.35 billion by 2030, advancing at a 3.42% CAGR. This growth pace reflects a mature competitive field in which conventional neutralizing products contend with proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs). Demand stability rests on demographic forces, notably a rapidly expanding cohort of adults aged 65 and above who experience higher rates of gastroesophageal reflux disease (GERD) and related acid disorders. Consumption patterns also track the global spread of sedentary lifestyles and diets rich in processed foods, both of which raise reflux incidence. Retail pharmacies continue to anchor over-the-counter (OTC) availability, yet digital commerce is accelerating their reach by blending in-store service with app-based fulfillment. Meanwhile, formulation science is reshaping consumer expectations, as gummies, soft-gels, and alginate-based "raft" products move from novelty to mainstream, helped by improved taste-masking and controlled-release technologies.

Global Antacids Market Trends and Insights

Aging Population and Rising Incidence of Gastrointestinal Disorders

Higher life expectancy is pushing the prevalence of acid-related conditions upward. In the United States, 51.5% of Medicare beneficiaries carried a digestive diagnosis in 2024 compared with 24.2% on Medicaid, underscoring an age-skewed disease burden. Physiologic shifts-such as reduced gastric buffering and drug-induced mucosal irritation-drive sustained purchases of antacid products among seniors. Polypharmacy complicates the picture; concurrent use of NSAIDs, anticoagulants, and corticosteroids heightens reflux and gastritis risk. Japanese cohort studies further signal nutritional trade-offs, noting that 16% of health-check participants took antacids and showed lower pre-albumin levels, hinting at protein absorption challenges. Together these trends support long-horizon volume growth in the antacids market.

Unhealthy Dietary Habits and Sedentary Lifestyles

Urban dietary patterns rich in fried foods, sugar, and carbonated beverages align with rising reflux incidence. Regional contrasts illustrate the effect: Turkey registered a 22.4% GERD prevalence, while China posted only 4.16%, a gap largely tied to eating habits and body-mass indices. Office-based work and reduced physical activity slow gastric motility and amplify stress-related acid secretion. In the United States alone, the annual direct cost burden of GERD now exceeds USD 10 billion, elevating OTC antacid use as a first-line defense. Co-morbid diabetes adds another layer; 73% of diabetic patients report bloating versus 67% in non-diabetics, creating cross-category demand for antacid solutions.

Growing Adoption of Proton Pump Inhibitors and H2 Antagonists

Superior healing rates and 24-hour symptom suppression give PPIs and emerging P-CABs a pharmacologic edge. Vonoprazan achieved a 93% healing rate in erosive esophagitis trials compared with 85% for lansoprazole. Eisai's prescription-to-OTC switch of rabeprazole (Pariet S) has extended advanced acid blockers into mainstream retail, eroding share for short-duration antacids. Japanese health-economic studies report lower three-year GERD costs when therapy begins with a P-CAB rather than a PPI, reinforcing the long-term shift.

Other drivers and restraints analyzed in the detailed report include:

Over-The-Counter Accessibility and Self-Medication Culture / Innovation in Formulation and Delivery Technologies / Safety Concerns Related to Chronic Antacid Consumption /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tablet forms remain dominant, with 25.56% of antacids market share in 2024, yet gummy and chewable soft-gel formats are rising at a 5.67% CAGR, redefining consumer expectations for taste and convenience. Single-dose portability and familiar confectionery textures draw first-time users, especially in the 18-35 demographic. Advances in polymer coating and micro-encapsulation have resolved longstanding bitterness issues, allowing higher drug loads without flavor compromise. Liquids and suspensions continue to serve pediatric and geriatric niches, benefiting from immediate bioavailability and ease of swallowing.

Competitive positioning now hinges on sensory experience as much as pharmacodynamics. Manufacturers are adding digestive enzymes, probiotics, or vitamin fortification to gummies, framing them as holistic digestive aids rather than reactive remedies. Scalable pectin- and gelatin-based molding lines deliver batch consistency while accommodating novel colors and shapes that boost shelf appeal. Effervescent granules, meanwhile, build a bridge between solid convenience and liquid speed, activating in water to form palatable drinks. Tablets are fighting back with orodispersible formats that dissolve quickly in the mouth, reducing time to relief and seeking to reclaim share in the evolving antacids market.

Calcium carbonate anchored 38.54% of the antacids market size in 2024, favored for its dual role in neutralizing acid and supplementing calcium intake. Yet alginate-based systems are expanding fastest at a 5.23% CAGR, drawing clinical support for their raft-forming barrier that prevents reflux episodes without systemic absorption. Gaviscon's alginate platform has demonstrated lower esophageal acid exposure and improved nighttime symptom control versus magnesium-aluminum blends. Combination therapies pair alginates with simethicone to tackle gas and acid in one dose, reinforcing adherence.

Magnesium hydroxide and oxide deliver rapid pH elevation but carry laxative effects that curb chronic use. Aluminum compounds are losing favor over neurologic safety worries, especially in renal-compromised seniors. Sodium bicarbonate retains emergency-room relevance for acute hyperacidity owing to its immediate neutralization but high sodium load restricts home use. Recent prototypes fuse magnesium alginate with proton pump micro-granules, offering immediate and prolonged relief in a single chewable tablet. This layered approach typifies the innovation race within the antacids market.

The Antacids Market Report is Segmented by Formulation Type (Tablets, and More), Active Ingredient Type (Calcium Carbonate, Magnesium Compounds, and More), Indication (Heartburn, Gastroesophageal Reflux Disease (GERD), and More), Route of Administration (Oral Solid, and More), Distribution Channel (Hospital Pharmacies, and More), Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America commanded 42.45% of antacids market revenue in 2024, anchored by high disposable incomes, strong self-medication culture, and well-established pharmacy chains. Widespread direct-to-consumer advertising keeps brand awareness high, while prescription-to-OTC switches introduce advanced agents that maintain consumer loyalty within the category. The United States also hosts many innovation centers, as evidenced by Sun Pharmaceutical's USD 100 million R&D expansion in New Jersey aimed at speeding specialty generic launches. Canadian demand aligns closely with U.S. trends, though provincial reimbursement policies add regional nuances in brand selection.

Europe presents a contrasting maturity scenario. Strict Health Technology Assessment (HTA) processes and price referencing apply downward pressure on retail margins, yet sustained GERD prevalence upholds baseline volume. Environmental priorities spur demand for plant-based actives and recyclable packaging, encouraging local suppliers to differentiate on sustainability credentials. France and Germany remain prescription-heavy markets, but Italy and Spain exhibit higher OTC penetration due to differing insurance co-payment structures. Regulatory recalibration, such as the European Union's ongoing evaluation of aluminum exposure limits, could redirect product development toward low-aluminum alternatives.

Asia-Pacific is the momentum story, projected at a 4.56% CAGR-well above the global average. Rising middle-class purchasing power and dietary westernization in India, Indonesia, and the Philippines feed demand for convenient reflux remedies. Market-entry barriers are easing as governments streamline OTC registration to widen access to primary care substitutes. Public-private collaborations, exemplified by India's Ayushman Bharat digital health initiative, integrate teleconsultation and e-pharmacy services, weaving antacids into chronic-disease management bundles. Japan, already a high-consumer but aging market, is shifting to P-CAB therapies, yet still ranks among the top per-capita purchasers of alginate products.

The Middle East and Africa hold modest share but offer rising opportunity as healthcare infrastructure improves. Gulf Cooperation Council states import premium antacid brands to satisfy expatriate populations, while Nigeria and Kenya exhibit grassroots growth in sachet-sized calcium carbonate powders sold through informal kiosks. South America occupies an intermediate position; Brazil's domestic manufacturing base supports competitively priced generics, whereas Argentina's inflation volatility affects stocking decisions at pharmacy chains. Across all developing regions, mobile-first e-commerce provides rural communities with access to branded antacids market products previously confined to urban centers.

List of Companies Covered in this Report:

Bayer / Haleon Plc / Johnson & Johnson (Kenvue) / Sun Pharmaceuticals Industries / Sanofi / WellSpring Pharmaceutical / Advance Pharmaceutical / CVS Health / Safetec Of America Inc. / Reckitt Benckiser Group / Takeda Pharmaceuticals / Procter & Gamble / Perrigo Company / Dr. Reddy's Laboratories / AstraZeneca / GlaxoSmithKline / Pfizer / Abbott Laboratories / AdvaCare / Akums Drugs & Pharmaceuticals Ltd. / Lil' Drug Store Products Inc. / Adcock Ingram Holdings Ltd. / Novartis /

Additional Benefits:

 The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
5.6.5.3.1 GCC

6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Bayer AG
6.3.2 Haleon Plc
6.3.3 Johnson & Johnson (Kenvue)
6.3.4 Sun Pharmaceutical Industries Ltd.
6.3.5 Sanofi S.A.
6.3.6 WellSpring Pharmaceutical Corporation
6.3.7 Advance Pharmaceutical Inc.
6.3.8 CVS Health Corporation
6.3.9 Safetec Of America Inc.
6.3.10 Reckitt Benckiser Group Plc
6.3.11 Takeda Pharmaceutical Company Ltd.
6.3.12 Procter & Gamble Co.
6.3.13 Perrigo Company Plc
6.3.14 Dr. Reddy's Laboratories Ltd.
6.3.15 AstraZeneca Plc
6.3.16 GlaxoSmithKline Plc
6.3.17 Pfizer Inc.
6.3.18 Abbott Laboratories
6.3.19 AdvaCare Pharma
6.3.20 Akums Drugs & Pharmaceuticals Ltd.
6.3.21 Lil' Drug Store Products Inc.
6.3.22 Adcock Ingram Holdings Ltd.
6.3.23 Novartis AG

7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

SCOTTS INTERNATIONAL

Antacids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-08-01 | 115 pages | Mordor Intelligence

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$4750.00
	Team License (1-7 Users)	$5250.00
	Site License	$6500.00
	Corporate License	$8750.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-02-26
		Signature	